首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

2126343

診斷生物標記市場：策略性洞察與預測（2026-2035）

Diagnostic Biomarkers Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月04日 | 出版商:

Knowledge Sourcing Intelligence | 英文 178 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計診斷生物標記市場將從 2026 年的 283.2 億美元成長到 2035 年的 628.2 億美元，複合年成長率為 9.3%。

診斷生物標記市場正經歷重大變革，其驅動力是精準醫療和基於生物標記的臨床決策模式轉移。這一市場演變的特點是，在多個疾病領域，人們日益認知到可測量的生物學特徵對於疾病早期檢測、患者分層、治療方案選擇和治療進展監測至關重要。次世代定序、多重免疫檢測、數位病理學和人工智慧 (AI) 等先進分子技術的融合，正在推動更全面、更標準化的生物標記發現和檢驗。隨著疾病變得日益複雜，對更早期、更個人化的臨床干預的需求不斷成長，促使醫療保健系統更廣泛地採用基於生物標記的診斷方法。基於生物標記的臨床試驗正在改善患者選擇並提高治療成功率，促使製藥公司擴大在伴隨診斷領域的合作。隨著對液態生物檢體技術、多組體學平台和人工智慧驅動的解讀工具的大量投資，診斷生物標記正逐漸成為全球醫療保健領域精準醫療的核心驅動力。

市場促進因素

精準腫瘤學的擴展是診斷生物標記市場的主要驅動力。精準腫瘤學是推動市場成長的最強勁的結構性因素之一，因為標靶治療需要在治療開始前識別特定的分子突變。隨著腫瘤學家致力於提高治療反應率並最大限度地減少不必要的毒性，對利用基因組學和蛋白質組學進行生物標記檢測的需求日益成長。由於基因明確的患者群體能夠改善治療結果，臨床試驗申辦方正在基於生物標記擴大其受試者招募策略。這種轉變正在推動對涵蓋多種癌症適應症的綜合生物標記組合的長期需求，從而持續擴大診斷生物標記的應用。多體學技術透過促進綜合生物標記的發現，進一步加速了市場成長。生物標記的開發依賴於對疾病機制的全面生物學表徵。定序平台、轉錄組學、蛋白質組學、代謝體學和太空生物學技術正在不斷產生整合資料集，從而識別具有臨床意義的分子特徵。由於單一生物標記方法往往無法捕捉疾病的異質性，研究機構正在擴展多組體學計畫。這一發展趨勢不斷擴大了腫瘤學、神經病學、循環系統醫學和罕見疾病等領域中具有臨床應用價值的生物標記範圍。液態生物檢體正在改變疾病監測和早期檢測的方式。液態生物檢體能夠偵測循環腫瘤DNA、循環性腫瘤細胞、細胞外囊泡和其他生物標記。由於血液檢測無需進行侵入性組織切片檢查即可進行重複監測，臨床需求正日益轉向血液檢測。隨著治療抗藥性的隨時間推移而變化，醫療保健提供者正在將縱向生物標記評估納入疾病管理。這種能力提高了診斷檢測的頻率，同時支持個別化治療方案的調整。人工智慧（AI）正在提高臨床解讀和診斷的一致性。大規模生物標記資料集需要進行複雜的電腦分析才能做出有意義的臨床決策。臨床醫生需要快速且標準化的報告，這促使人工智慧平台在解讀基因組變異、分析數位病理影像和確定生物標記優先順序方面得到越來越廣泛的應用。技術開發人員正在將機器學習整合到診斷工作流程中，而醫療系統也在擴展其數位病理基礎設施。

市場限制因素

監管機構要求在商業化之前提供強力的證據，證明其分析有效性、臨床有效性和臨床效用，這使得臨床有效性要求仍然十分嚴格。這些嚴格的證據要求為研發人員帶來了巨大的時間和成本負擔。即使有強力的科學證據支持，不同醫療保健系統中更廣泛的報銷政策也限制了某些先進生物標記檢測的常規應用。保險覆蓋範圍的區域差異給診斷服務提供者帶來了不確定性，並限制了患者的就醫途徑。生物標記發現過程中經常會遇到候選標記在後期檢驗階段合格的情況，導致研發週期延長和研發成本增加。如此高的失敗率對持續投資新型生物標記研發構成了挑戰。此外，複雜且因地理而異的法規也給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

依生物標誌類型
- 基因生物標記
- 蛋白質生物標記
- 組織學標誌物
- 其他
透過技術平台
- 聚合酵素鏈鎖反應（PCR）
- 次世代定序（NGS）
- 免疫測量
- 原位雜合反應（ISH）
- 其他分子技術
依樣本類型
- 血
- 組織
- 尿
- 唾液
- 腦脊髓液（CSF）
- 其他體液
臨床應用
- 腫瘤學
- 心血管疾病
- 神經病變
- 感染疾病
- 代謝性疾病
- 呼吸系統疾病
- 其他臨床用途
最終用戶
- 醫院
- 臨床實驗室
- 學術研究機構
- 製藥和生物技術公司
- 其他

第10章全球診斷生物標記市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球診斷生物標記市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
墨西哥
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
QIAGEN NV
Abbott Laboratories
Natera Inc..
Tempus Labs
Illumina, Inc.
Agilent Technologies, Inc.
Exact Sciences
Myriad Genetics

第14章全球診斷生物標記市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009055

The Diagnostic Biomarkers Market is expected to grow at a CAGR of 9.3% from a market value of USD 28.32 billion in 2026 to USD 62.82 billion in 2035.

The diagnostic biomarkers market is undergoing significant transformation driven by the paradigm shift toward precision medicine and biomarker-guided clinical decision-making. The market's evolution is characterized by the growing recognition that measurable biological characteristics are essential for early disease detection, patient stratification, treatment selection, and therapeutic monitoring across multiple disease areas. The convergence of advanced molecular technologies, including next-generation sequencing, multiplex immunoassays, digital pathology, and artificial intelligence, is enabling more comprehensive and standardized biomarker discovery and validation. Healthcare systems are increasingly adopting biomarker-guided diagnostics because rising disease complexity requires earlier and more individualized clinical intervention. Pharmaceutical companies are expanding companion diagnostic collaborations because biomarker-guided clinical trials improve patient selection and increase therapeutic success rates. The market is witnessing significant investment in liquid biopsy technologies, multi-omics platforms, and AI-enabled interpretation tools, positioning diagnostic biomarkers as a core enabler of precision healthcare across global medical practice.

Market Drivers

The expansion of precision oncology represents the primary driver for the diagnostic biomarkers market. Precision oncology represents one of the strongest structural drivers because targeted therapies require identification of specific molecular alterations before treatment initiation. Demand is increasingly shifting toward genomic and proteomic biomarker testing as oncologists seek to improve treatment response while minimizing unnecessary toxicity. Clinical trial sponsors are expanding biomarker-driven enrollment strategies because genetically defined patient populations improve therapeutic outcomes. This transition strengthens long-term demand for comprehensive biomarker panels across multiple cancer indications, resulting in sustained growth in diagnostic biomarker utilization. Multi-omics technologies are further accelerating market growth by enabling comprehensive biomarker discovery. Biomarker development depends on comprehensive biological characterization of disease mechanisms. Sequencing platforms, transcriptomics, proteomics, metabolomics, and spatial biology technologies are increasingly generating integrated datasets that identify clinically relevant molecular signatures. Research organizations are expanding multi-omics programs because single-biomarker approaches frequently fail to capture disease heterogeneity. This evolution supports the continuous expansion of clinically actionable biomarkers across oncology, neurology, cardiovascular medicine, and rare diseases. Liquid biopsy is transforming disease monitoring and early detection through minimally invasive sampling. Liquid biopsy enables the detection of circulating tumor DNA, circulating tumor cells, extracellular vesicles, and other biomarkers through minimally invasive sampling. Clinical demand is increasingly shifting toward blood-based testing because repeated monitoring becomes feasible without invasive tissue biopsies. Healthcare providers are incorporating longitudinal biomarker assessment into disease management as treatment resistance evolves over time. This capability expands diagnostic testing frequency while supporting personalized therapeutic adjustment. Artificial intelligence is improving clinical interpretation and diagnostic consistency. Large biomarker datasets require sophisticated computational interpretation before meaningful clinical decisions become possible. AI platforms are increasingly supporting genomic variant interpretation, digital pathology image analysis, and biomarker prioritization because clinicians require rapid and standardized reporting. Technology developers are integrating machine learning into diagnostic workflows while healthcare systems expand digital pathology infrastructure.

Market Restraints

Clinical validation requirements remain extensive because regulatory authorities require strong evidence demonstrating analytical validity, clinical validity, and clinical utility before commercialization. The rigorous evidence requirements create significant time and cost burdens for developers. Reimbursement policies differ considerably across healthcare systems, limiting routine adoption of several advanced biomarker tests despite strong scientific evidence. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Biomarker discovery frequently identifies candidate markers that fail during late-stage validation, increasing development timelines and research expenditure. The high failure rate creates challenges for sustained investment in novel biomarker development. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated multi-omics platforms and AI-enabled interpretation. Genetic biomarkers constitute the largest technological foundation because they directly identify inherited and acquired molecular alterations associated with disease development. Demand is increasingly shifting toward comprehensive genomic profiling as physicians require actionable molecular information before selecting targeted therapies. Diagnostic manufacturers are expanding NGS panels that simultaneously evaluate numerous genetic alterations while improving laboratory efficiency. Protein biomarkers continue supporting established diagnostic applications, including immunoassays for cardiac and infectious disease markers. Histologic biomarkers remain essential for tissue-based diagnosis and classification. Blood-based diagnostics represent the fastest-evolving sample category because minimally invasive collection enables repeated clinical monitoring throughout disease progression. Healthcare providers are increasingly adopting liquid biopsy technologies as serial molecular assessment reduces dependence on surgical tissue acquisition. Oncology remains the largest clinical application because targeted cancer therapies increasingly depend on validated biomarker identification before treatment initiation. Demand is continuously shifting toward comprehensive molecular characterization as therapeutic options become more genetically specific. Cardiovascular diseases, neurological disorders, infectious diseases, metabolic disorders, and respiratory illnesses continue expanding biomarker utilization. Clinical laboratories represent the leading end-user segment, with hospitals and academic research institutes expanding testing capabilities. Pharmaceutical and biotechnology companies are increasing biomarker utilization for drug discovery and development. The integration of AI is becoming increasingly important because large biomarker datasets require sophisticated computational interpretation before meaningful clinical decisions become possible. AI platforms are increasingly supporting genomic variant interpretation, digital pathology image analysis, and biomarker prioritization.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and life science companies alongside specialized precision medicine and AI-driven analytics providers. Roche remains strategically distinct because it combines one of the world's largest pharmaceutical portfolios with a comprehensive diagnostics business, enabling integrated development of therapeutics and companion diagnostics, strengthening clinical adoption and regulatory alignment across precision medicine. Thermo Fisher Scientific differentiates itself through an extensive portfolio of laboratory instruments, molecular diagnostic technologies, sequencing workflows, reagents, and bioinformatics solutions supporting both clinical diagnostics and biomedical research. QIAGEN maintains strategic differentiation through its expertise in molecular diagnostics, sample preparation technologies, companion diagnostics, and clinical bioinformatics, supporting biomarker discovery, validation, and routine clinical implementation across multiple disease areas. Abbott leverages its diversified diagnostics portfolio to integrate biomarker testing across immunoassays, molecular diagnostics, point-of-care systems, and clinical laboratory platforms. Natera specializes in cell-free DNA technologies that support oncology, reproductive health, and organ transplant diagnostics, establishing a strong competitive position through personalized molecular residual disease testing and highly sensitive circulating tumor DNA analysis. Tempus AI differentiates itself through the integration of AI, multimodal clinical data, genomic sequencing, digital pathology, and real-world evidence into precision medicine workflows. Companies are pursuing product portfolio expansion through innovation in multi-omics platforms, liquid biopsy assays, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Recent key developments include the Alzheimer's Drug Discovery Foundation announcing the next phase of its Diagnostics Accelerator will fund next-generation biomarkers to support Alzheimer's precision medicine worldwide. Quanterix announced submission of a 510(k) premarket notification for a blood-based algorithmic test designed to help assess Alzheimer's disease using multiple biomarkers. Fujirebio announced a new fully automated neuro-testing offering for research use, extending its blood-based Alzheimer's biomarker portfolio on the Lumipulse platform. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The diagnostic biomarkers market is positioned for sustained growth driven by the convergence of precision medicine, technological innovation, and expanding healthcare investment. The transition from conventional diagnostic approaches toward biomarker-guided clinical decision-making represents a fundamental shift in healthcare delivery. While challenges related to clinical validation, reimbursement variability, and discovery failure persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with diagnostic biomarkers evolving into a core enabler of precision healthcare, supporting earlier disease detection, personalized treatment selection, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Diagnostic Biomarkers Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Disease Burden and Clinical Importance of Diagnostic Biomarkers
3.8 Disease Prevalence Analysis
3.9 Diagnosed Patient Population Analysis
3.10 Testing Volume Analysis
3.11 Biomarker Development and Clinical Validation Landscape
3.12 Biomarker Adoption Across Disease Areas

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Biomarker Technologies
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 AI Integration in Biomarker Discovery and Diagnostics
6.6 Multi-Omics and Digital Biomarker Integration

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Diagnostic Biomarkers Market Landscape Analysis

8.1 Analysis by Biomarker Type
8.2 Analysis by Technology Platform
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology
8.6 Analysis by End User

9. Global Diagnostic Biomarkers Market Segment Analysis (2021-2035)

9.1 By Biomarker Type
- 9.1.1 Genetic Biomarkers
- 9.1.2 Protein Biomarkers
- 9.1.3 Histologic Biomarkers
- 9.1.4 Others
9.2 By Technology Platform
- 9.2.1 Polymerase Chain Reaction (PCR)
- 9.2.2 Next-Generation Sequencing (NGS)
- 9.2.3 Immunoassays
- 9.2.4 In Situ Hybridization (ISH)
- 9.2.5 Other Molecular Technologies
9.3 By Sample Type
- 9.3.1 Blood
- 9.3.2 Tissue
- 9.3.3 Urine
- 9.3.4 Saliva
- 9.3.5 Cerebrospinal Fluid (CSF)
- 9.3.6 Other Body Fluids
9.4 By Clinical Application
- 9.4.1 Oncology
- 9.4.2 Cardiovascular Diseases
- 9.4.3 Neurological Disorders
- 9.4.4 Infectious Diseases
- 9.4.5 Metabolic Disorders
- 9.4.6 Respiratory Diseases
- 9.4.7 Other Clinical Applications
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Clinical Laboratories
- 9.5.3 Academic & Research Institutes
- 9.5.4 Pharmaceutical & Biotechnology Companies
- 9.5.5 Others

10. Global Diagnostic Biomarkers Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Diagnostic Biomarkers Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia
11.16 South Africa

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Thermo Fisher Scientific Inc.
13.3 QIAGEN N.V.
13.4 Abbott Laboratories
13.5 Natera Inc..
13.6 Tempus Labs
13.7 Illumina, Inc.
13.8 Agilent Technologies, Inc.
13.9 Exact Sciences
13.10 Myriad Genetics